knowledge -WSS

knowledge

author：hotspot 2025-09-29 08:06:33 Page View：5

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

David Ricks of Eli Lilly: best biopharma CEO of 2023

HyacinthEmpinado/STATIt’sthattimeoftheyearagainwhenIrecognizetheBestBiopharmaCEOoftheyear.Thisyear’s

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

What STAT readers think about the FDA and patient advocacy

MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

knowledge

explore

focus

What STAT readers think about the FDA and patient advocacy